Compare ConocoPhillips (COP) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Incyte Corporation — how do they compare? ConocoPhillips trades at $133.28 (market cap $161.21B), while Incyte Corporation trades at $112.75 (market cap $22.85B). The key difference: ConocoPhillips is far larger — about 7.1× Incyte Corporation's market cap, and ConocoPhillips pays a 2.5% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Incyte Corporation for 33 Days on average.
| COP | INCY | |
|---|---|---|
Market Cap | $161.21B | $22.85B |
Volume | 6,058,403 | 1,927,029 |
Sector | Energy | Health |
52-Week High | $141.22 | $129.93 |
52-Week Low | $85.66 | $83.80 |
Typical Hold Time | 79 Days | 33 Days |
Enterprise Value | $176.81B | $18.35B |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $129.84, up 0.38% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a net income margin of 14.65% and a P/E of 17.17, while recent earnings beat expectations in Q1 and Q2 2026. A 20-year LNG supply deal with Venture Global, announced October 1, 2026, highlights strategic growth initiatives.
The outlook is positive, supported by a 75% analyst buy rating and a consensus price target of $154.75, implying 19% upside. Risks include geopolitical exposure in the Middle East and oil price volatility, but robust cash flow and shareholder returns provide stability for investors.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
